

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Grainger et al. Customer No. : 21003
Serial No. : 09/754,775 Group Art Unit : 1617
Filed : 01/04/2001
Examiner : Kim, Jennifer M.
For : PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN ANALOGUES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as First-Class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,
on:

August 4, 2006
Date of Deposit

Van Nguyen
Attorney Name


Signature

56,571
PTO Reg. No.

August 4, 2006
Date of Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicant brings to the attention of the Examiner the document listed on the attached Form PTO-1449 and respectfully requests that the listed document be considered by the Examiner and made of record in the above-captioned application.

1. Sato, Yasufumi. "TGF- β and Vascular Lesions: Neoangiogenesis and Atherosclerosis", Experimental Medicine [Jikken igaku], Chapter 2: TGF- β Pathophysiology, Vol. 10, No. 15, 1992, pp. 94-98 (1908-1912).

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed document is material or constitutes "prior art." If the Examiner applies the document as prior art against any claim in the application and the applicant determines that the cited document does not constitute "prior art" under United States law, the applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of the document.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should the document be applied against the claim of the present application.

This Information Disclosure Statement is being filed after the mailing date of a first office action. Therefore, applicants have authorized the Commissioner to charge the fee of \$180.00 to our deposit account. If any additional fee is due, the Commissioner is authorized to charge any such fee or credit any overpayment, to our Deposit Account No. 02-4377.

Respectfully submitted,

BAKER BOTTS L.L.P.

By:


Xan Nguyen
Patent Office Reg. No. 56,571

30 Rockefeller Plaza, 44th Floor
New York, NY 10012-4498
Attorneys for Applicants
212-408-2500

Enclosures

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. 074973.0117	Serial No. 09/754,775
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(Use several sheets if necessary)			
		Applicant Grainger et al.	
		Filing Date January 4, 2001	Group 1617
		Examiner Kim, Jennifer M.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	1.	Sato, Yasufumi. "TGF-β and Vascular Lesions: Neoangiogenesis and Atherosclerosis", Experimental Medicine [Jikken igaku], Chapter 2: TGF- β Pathophysiology, Vol. 10, No. 15, 1992, pp. 94-98 (1908-1912).	

NY02:556492.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.